Scientists Find Progress With Anti Aging Research

Panama City, US, 03/17/2014 / SubmitMyPR /

An international team of scientists has been working on researching anti aging drugs, and is making progress. As every day moves on, the silico research process gets scientists closer to discovering a way to reverse the aging process in humans. Age reduction has been successful in laboratory animals, up to a thousand percent, however in humans, the research is still being conducted.

A team of ambitious and excited scientists, from all around the world, continue researching a new drug that could reverse the aging process in humans. Following the launch of Calico in September of 2013, and the launch of Human Longevity Inc. just last week, the anti aging secrets are becoming closer to being revealed.

Silico Medicine, a company utilizing advanced bioinformatics approaches to find new drugs that will combat aging, has recently opened its doors in Baltimore, MD. The international team, comprised of biogerontologists, geneticists, computer scientists and biomathematicians prpopsed using a computer simulation and laboratory validation approach, using human cells and model organisms to predict what drugs may help fight aging in humans. The team recently published a paper describing the method in "Frontiers In Genetics," a reputable Scientific Journal.

The Human Genome Project and the following revolution in sequencing and laboratory diagnostics resulted in the vast data on genetic and epigenetic profiles of cells and tissues from people of various ages. The proposed method uses this data to construct the cloud of molecular signalling pathways involved in aging and longevity and evaluates the effects of the very large number of drugs and drug combinations to simulate the young state of the cells and tissues. Scientists hope that this method may be used to find new drugs with aging-suppressive properties and predict the activity of the drugs that are already on the market. Also, people respond to the drugs differently and this method may be able to personalize the geroprotective therapy to the individual patients and help the drug companies conduct better clinical trials.

"We are at the point of human history, where we can no longer afford to have aging continue taking the lives of millions of people and putting the extra toll on the world’s economy. We need new geroprotectors in clinical practice and we need them now", said Alex Zhavoronkov, PhD, the CEO of In Silico Medicine. "Also, people are different, age at different rates and respond to drugs differently. The proposed method may be used to predict the personalized geroprotector regiments.", he added.

Many pharmaceutical companies already expressed their interest in bringing aging research into clinical practice, but the absence of the business models, accurate validation methods, and the inability to classify aging as the curable disease are major impediments to mainstream development of geroprotective drugs. In silico drug discovery may help accelerate this process. The group plans to present the results of their experimental work using this method at the Practical Applications of Aging Research Symposium at MipTek 2014 in Basel, Switzerland attended by over 3,000 delegates from the pharmaceutical industry. .

The paper describing the new approach to screening and ranking of geroprotective drugs was published in the reputable scientific journal Frontiers in Genetics.

Citation:

Zhavoronkov A, Buzdin AA, Garazha AV, Borissoff N and Moskalev AA (2014). Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front. Genet. 5:49. doi: 10.3389/fgene.2014.00049 - See more at: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/abstract#sthash.2qpLbytY.dpuf